Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
AVANOS MEDICAL, INC. SVP and Chief Financial Officer Scott Michael Galovan reported a compensation-related share transaction. On April 22, 2026, 4,228 shares of common stock were surrendered to the company to satisfy tax withholding obligations when 12,225 time-based restricted share units vested. This was a tax-withholding disposition rather than an open-market sale. After the transaction, Galovan directly held 135,596 shares of common stock.
Avanos Medical senior vice president of operations Sigfrido Delgado had shares withheld to cover taxes on a stock award. On the vesting of 16,300 time-based restricted share units, 4,264 shares of common stock were surrendered to Avanos Medical to satisfy tax withholding obligations. Each restricted share unit is economically equivalent to one common share. Following this non-market tax-withholding disposition, Delgado directly holds 55,741 shares of Avanos Medical common stock.
AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported a routine tax-related share disposition. He surrendered 21,194 shares of Common Stock at $14.53 per share to the company to cover tax withholding due when 72,614 time-based restricted share units vested. After this tax-withholding transaction, he directly holds 322,194 shares of Common Stock.
Avanos Medical, Inc. has agreed to be acquired by affiliates of American Industrial Partners in an all-cash merger. Avanos stockholders will receive $25.00 per share in cash, valuing the company at an enterprise value of approximately $1.272 billion and representing a 72.1% premium to the April 13, 2026 closing price and an 82.8% premium to the 30-day volume-weighted average price.
The Board unanimously approved the Agreement and Plan of Merger and recommends stockholders adopt it. Closing is expected in the second half of 2026, subject to approval by a majority of outstanding shares, antitrust and other regulatory clearances, and other customary conditions; the merger is not subject to a financing condition and is backed by an equity commitment from American Industrial Partners Capital Fund VIII, L.P. After completion, Avanos will become a private company and its common stock will be delisted from the New York Stock Exchange.
Avanos Medical senior vice president of operations Sigfrido Delgado received new equity compensation awards. He was granted 37,520 employee stock options with an exercise price of $13.69 per share, expiring on March 13, 2036, along with 15,886 time-based restricted share units.
The restricted share units are scheduled to vest in installments between March 13, 2027 and March 13, 2029, and each unit represents one share of common stock. Following these grants, Delgado directly holds 59,434 stock options and 60,005 shares of Avanos Medical common stock. These are compensation awards, not open-market purchases.
Avanos Medical SVP and CFO Scott Michael Galovan received new equity awards. He was granted employee stock options for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,212 shares.
He also received 29,481 shares of Common Stock as a grant, increasing his direct share ownership to 139,824 shares. These awards include time-based restricted share units that vest in scheduled installments on March 13, 2027, March 13, 2028 and March 13, 2029, aligning a portion of his compensation with the company’s long-term performance.
Avanos Medical Chief Executive Officer David Pacitti received new equity awards in the form of stock options and restricted share units. On March 13, 2026, he was granted options to purchase 239,354 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036.
He also received 101,341 time-based restricted share units, each equivalent to one share of Common Stock, increasing his direct Common Stock holdings to 343,388 shares after the grant. These awards vest over three years, with portions scheduled to vest on March 13, 2027, March 13, 2028, and March 13, 2029, aligning his compensation with the company’s long-term performance.
Avanos Medical SVP of Operations Sigfrido Delgado received new equity awards. He was granted 37,782 employee stock options to buy Common Stock at $13.69 per share, expiring on March 13, 2036. He was also granted 15,886 time-based restricted share units that vest in stages between March 2027 and March 2029.
Following these awards, he directly holds 59,696 stock options and 60,005 shares of Common Stock. The TRSUs are the economic equivalent of common shares but will only convert into stock as they vest under Avanos Medical's 2021 Long Term Incentive Plan.
AVANOS MEDICAL, INC. Chief Executive Officer David Pacitti reported equity compensation grants. He received an employee stock option for 241,021 shares of common stock at an exercise price of $13.69 per share, expiring on March 13, 2036. He also received 101,341 shares of common stock as a grant, bringing his directly held common stock to 343,388 shares after the transaction. Footnotes state the awards are time-based restricted share units under the 2021 Long Term Incentive Plan and will vest in three installments on March 13, 2027, 2028, and 2029 under specified vesting percentages.
AVANOS MEDICAL, INC. reported that its SVP and Chief Financial Officer, Scott Michael Galovan, received new equity awards as part of his compensation. He was granted an employee stock option for 70,115 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,697 options after the grant.
He also received 29,481 time-based restricted share units (TRSUs), increasing his direct Common Stock holdings to 139,824 shares after the award. According to the footnotes, one TRSU equals one share of Common Stock, with vesting in tranches on March 13, 2027, March 13, 2028, and March 13, 2029.